New treatments for depression

New research has revealed a method of repurposing existing drugs as novel treatments for depression, using laboratory studies of brain cells. 

New research has revealed a method of repurposing existing drugs as novel treatments for depression, using laboratory studies of brain cells.  The work was primarily funded by the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre and Dementia Unit, a partnership between South London and Maudsley NHS Foundation Trust and King’s College London.

The results reflect a growing movement towards repurposing drugs that have been developed for one condition to tackle another. This approach effectively bypasses the discovery phase of drug development, which could save significant time and money in finding effective treatments.

Finding ways to fast-track the discovery of new antidepressants is crucial as around half of all people diagnosed with depression do not respond to first-line treatments.

Published in the Journal of Psychopharmacology, this new study measured the effects of two types of antidepressant on levels of gene activity in specific brain cells, which have previously been shown to be altered in depressed patients and are the catalyst for the action of some antidepressants.

Using a method known as ‘connectivity mapping’, the researchers identified gene activity signatures unique to antidepressants. They then searched for the same or very similar signatures in a database of more than 1,300 medications that are currently used to treat a wide range of illnesses. 

This process identified two drugs with the same signatures as antidepressants tested in the first part of their study, which means they could have the potential to be repurposed as treatments for depression. The two drugs identified using this process will now be tested to discover whether they are clinically effective treatments for depression.

Dr Sandrine Thuret, corresponding and joint senior author of the study, from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London, said:

Thanks to advances in technology we’re now using big data analytics to uncover molecular similarities between diseases, allowing researchers to identify drugs already used for one disorder that have the potential to be repurposed as treatments for another illness.

Dr Gerome Breen, joint senior author from the NIHR Maudsley Biomedical Research Centre, said:

The ability of genomics to provide tools for drug discovery has been utilised for a long time in cancer research, in particular. Now we have shown that this method can also work for mental health, providing valuable information about new drugs that could be investigated in depression.